Treatment of Bronchial Asthma with Unani Medicine Majoon-e-Rahul Momineen.

Phase 2

Not yet recruiting

• Conditions: Other and unspecified asthma, (2) ICD-10 Condition: J459||Other and unspecified asthma, (3) ICD-10 Condition: J459||Other and unspecified asthma, Zeeq un Nafas (Bronchial Asthma),

• Registration Number: CTRI/2018/08/015398
• Lead Sponsor: Central Council For Research In Unani Medicine

Brief Summary

This study is a multicentric open trial in patients with **Zeeq un Nafas (Bronchial Asthma)** After screening, Patients will be enrolled if they satisfy inclusion and exclusion criteria.  The patients will be assessed clinically at every  week.  This includes subjective assessment of general well being and physical examination . The total duration of treatment will be 2 weeks. Laboratory parameters for safety assessment will be conducted at baseline and on completion of the protocol therapy.

**Composition of *Majoon Rahul Momineen***

| | | | |

| --- | --- | --- | --- |

|**S.No.**

**Ingredients**

**Botanical**

**Quantity**

|1

Jauzbuwa

*Myristica fragrans* Houtt.

45gm

|2

Kateera

*Cochlospermum religiosum* (Linn.) *Alston*.

45gm

|3

Irsa

*Iris ensata* Thunb.

45gm

|4

Barg-e-Gaozaban

*Borago officinalis* Linn.

5gm

|5

Khusyat-us-Salab

*Orchis mascula* Linn.

5gm

|6

Tukhm-e-Gazar

*Daucus carota* Linn.

120gm

|7

Narjeel

*Cocos nucifera* Linn.

120gm

|8

Darchini

*Cinnamomum zeylanicum* Blume.

120gm

|9

Habb-e-Sanobar

*Pinus gerardiana* Wall.

120gm

|10

Shaqaq-ul-Misri

*Pastinaca secacul* Linn.

210gm,

|11

Sheera-e-Tukhm-e-Khashkhash

*Papaver somniferum* Linn.

300gm

|12

Joshanda-e-Post-e-Khashkhash

*Papaver somniferum* Linn.

600gm

|13

Asal or Qand Safaid

Honey or Sugar

5kg

|14

Aab-e-Seb

*Malus sylvestris* Mill.

1.2*ltr*

|15

Aab-e-Gazar

*Daucus carota* Linn.

 2*ltr*

Detailed Description

Not available

Study Timeline

• Study Start: 2018-08-21
• Last Update Posted: 2019-02-21

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

• Patients of either sex in the age group of 19-60 2.
• Patients of Bronchial Asthma presenting with the following symptoms: Wheeze Shortness of breath Chest tightness and cough that vary over time and in intensity Expiratory airflow limitation as suggested by a decreased FEV1 Patients with Asthma Control Questionnaire Score < 1.5.

Exclusion Criteria

• The patients of Zeequn Nafas (Bronchial Asthma) with following conditions will be excluded from the study: 1.
• Patient with Upper Respiratory Tract Infections, Chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema.
• Patient with medical conditions requiring long term treatment such as Pulmonary tuberculosis, Renal insufficiency Diabetes Mellitus, Hypertension etc 3.
• Patients with cognitive impairments 4.
• History of addiction (smoking, alcohol, drugs) 5.
• Pregnant and lactating women.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement in the sign and symptoms of Zeeq un Nafas (Bronchial Asthma)	Two Weeks

Secondary Outcome Measures

Name	Time	Method
Hematological and biochemical assessments for safety	2 weeks

Trial Locations

Locations (2)

Central Research Institute of Unani Medicine; 🇮🇳 Hyderabad, ANDHRA PRADESH, India

Regional Research Institute of Unani Medicine; 🇮🇳 JAMMU, & KASHMIR, India

Central Research Institute of Unani Medicine

🇮🇳Hyderabad, ANDHRA PRADESH, India

Dr Syed Gulnawaz Ahmad

Principal investigator

9997603371

skgulnawaz@gmail.com